Page last updated: 2024-11-05

ticlopidine and Myelodysplastic Syndromes

ticlopidine has been researched along with Myelodysplastic Syndromes in 2 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, M1
Chen, T1
Liang, C1
Xiang, X1
He, Z1
Wu, Z1
Wercules, O1
Meireles, GC1
Longhi, A1
Beltrão, P1
Pimenta, J1

Other Studies

2 other studies available for ticlopidine and Myelodysplastic Syndromes

ArticleYear
Myelodysplastic syndrome associated with clopidogrel: a case report.
    International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:1

    Topics: Aged; Clopidogrel; Female; Humans; Myelodysplastic Syndromes; Platelet Aggregation Inhibitors; Ticlo

2012
In-hospital and late outcomes after coronary stenting in patient with unstable angina and myelodysplastic syndrome.
    Arquivos brasileiros de cardiologia, 2006, Volume: 87, Issue:5

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Humans; Male; M

2006